Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINSPOT: Zolbetuximab + paclitaxel + ramucirumab in CLDN18.2+ gastro-esophageal adenocarcinoma (2nd line)
2025-521358-41-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zolbetuximab in gastroesophageal junction adenocarcinoma, sponsored by UZ Leuven. Primary endpoint: Overall survival. Planned start Sep 2025; status: authorised.
02
Drugs
zolbetuximab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2025-521358-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521358-41-00.